Primary Outcomes

Description: Observational measure of parent sensitivity during infant-parent interactions

Description: Parent-report questionnaire assessing degree of involvement with infants at home, reflecting percent time engaging in each activity. Subscales include: Direct Care, Indirect Care, Play Activities, and Total score all ranging from 0 - 100. Higher values mean higher percentage of time spent in that caretaking activity. Scores are averaged to create the subscales and total score.

Description: Parent-report questionnaire assessing degree of stress about roles as a parent. Subscales include: Parental Distress (scale range from 5 - 60; 33 and higher = 85th percentile); Parent-Child Dysfunctional Interaction (scale range 5 - 60; 26 and higher = 85th percentile); Difficult Child (scale range 5 - 60; 33 and higher = 85th percentile); Total Score (scale range 15 - 180; 86 and higher = 85th percentile). Higher values mean greater levels of parenting stress. Scores are summed to create subscales and the total score.

Description: Parent-report measure of self-efficacy in their role as a parent. Subscales include Satisfaction (cale range 9 - 54); Efficacy (scale range 8 - 48). Total Score (scale range 17 - 102). Higher values indicate a greater satisfaction, efficacy, and total sense of competence. Scores are summed to create the subscales and total score.

Description: Parent report questionnaire assessing parents' security in their relationships with each other. Subscales include Preoccupied Attachment (scale range 1 - 7); Fearful Attachment (scale range 1 - 7); Secure Attachment (scale range 1 - 7). Higher values mean greater levels of that type of attachment to spouse. Scores are averages of item sets.

Description: Parent report questionnaire assessing conflict strategies in spousal relationship. Subscales include Cooperation (scale range 0 - 36); Avoidance and Capitulation (scale range 0 - 60); Stonewalling (scale range 0 - 42); Verbal Aggression (scale range 0 - 48); Physical Aggression (scale range 0 - 42); Child Involvement (scale range 0 - 30); Conflict Resolution (scale range 0 - 39). Higher scores indicate greater levels of use of conflict strategies or greater resolution. Item sets are summed to create subscale scores.

Description: Parent report questionnaire assessing children's exposure to marital conflict. There is a total score (scale range 0 - 36). Higher values indicate more conflict. Items are summed to create the total score.

Description: Parent questionnaire evaluating children's behavior problems and competence. Subscales include Problems (scale range 0 - 66); Competencies (scale range 0 - 22); Externalizing problems (scale range 0 - 12); Internalizing (scale range 0 - 16); Dysregulation (scale range 0 - 16); Autism Spectrum Disorder (scale range 0 - 17). Higher scores indicate higher levels of each construct or higher screening value for Autism Spectrum Disorder. Scores are summed.

Description: Observational ratings of infant attachment security with mothers from the Strange Situation; with COVID-19, we no longer do in-person assessments so we now use a modified version of the Attachment Q-Sort which is an interview with mothers over zoom.

Description: Observational ratings of infant attachment security with fathers from the Strange Situation; with COVID-19, we no longer do in-person assessments so we now use a modified version of the Attachment Q-Sort which is an interview with fathers over zoom.

Description: Observational measure of parents' conflict styles during discussions

Description: Observational measure of infants' affective and regulatory behaviors during parent-child interactions and during couples' discussions

Primary Outcomes

Description: Defined as death or dependency on mechanical ventilation, renal replacement, or vasopressors

Secondary Outcomes

Description: Persistent organ dysfunction-free days in intensive care unit

Description: Mortality at 6 months

Description: Assessed by the questionnaire EuroQol-5D (EQ-5D-5L). The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'.

Description: Assessed by serum lactate concentration

Description: Assessed by the Sequential Organ Failure Assessment (SOFA) score. Used to track a person's status during the stay in an intensive care unit to determine the extent of a person's organ function or rate of failure. The score is based on 6 different sub-scores, one each for the respiratory (PaO2/FiO2 mmHg), cardiovascular (mean arterial pressure OR administration of vasopressors required), hepatic (liver bilirubin (mg/dl) [μmol/L]), coagulation (platelets×103/µl), renal (kidneys creatinine (mg/dl) [μmol/L] (or urine output)) and neurological (Glasgow coma scale). The sub-score of eah system ranges from 0 (best) to +4 (worst).

Description: Assessed by interleukin-1 beta (IL-1ß), tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP)

Description: Assessed by procalcitonin (PCT)

Description: Assessed by thrombomodulin (TM) and angiopoietin-2 (ANG-2)

Description: Assessed by KDIGO (Kidney Disease: Improving Global Outcomes) criteria

Description: clinician judgment of hemolysis, as recorded in the chart, OR hemoglobin drop of at least 25 g/L within 24 hours of a dose of investigational product PLUS 2 of the following: reticulocyte count >2 times upper limit of normal at clinical site lab; haptoglobin < lower limit of normal at clinical site lab; indirect (unconjugated) bilirubin >2 times upper limit of normal at clinical site lab; Lactate dehydrogenase (LDH) >2 times upper limit of normal at clinical site lab. Severe hemolysis: - hemoglobin < 75 g/L AND at least 2 of the above criteria AND requires 2 units of packed red blood cells

Description: Core lab-validated glucose level of less than 3.8 mmol/L

Description: Assessed by chromatography-tandem mass spectrometry

Description: Assessed by chromatography-tandem mass spectrometry

Description: Assessed by chromatography-tandem mass spectrometry

Primary Outcomes

Description: Will compare mean change scores across the two conditions (mindset and control) Minimum=1 Maximum=6 High=worse outcome

Description: Will compare mean change scores across the two conditions (mindset and control) Minimum=1 Maximum=5 High=better outcome

Description: Will compare mean change scores across the two conditions (mindset and control) Minimum=1 Maximum=5 High=better outcome

Description: Will compare mean performance as reflected in reaction time and accuracy across the two conditions (mindset and control)

Description: Will compare mean levels of self-reported emotion regulation strategies across the two conditions (mindset and control)

Description: Will compare mean levels of amygdala activation during relevant trials of the Social Evaluation Task and Go/no go Task across the two conditions (mindset and control)

Description: Will compare mean levels of frontal parietal network-amygdala connectivity during relevant trials of the Social Evaluation Task and Go/no go Task across the two conditions (mindset and control)

Description: Will compare mean change scores across the two conditions (mindset and control)

Secondary Outcomes

Description: Will compare mean change scores across the two conditions (mindset and control)

Description: Will compare mean change scores across the two conditions (mindset and control)

Description: Will compare mean change scores across the two conditions (mindset and control) Minimum=1 Maximum=5 High=better outcome

Description: Will compare mean change scores across the two conditions (mindset and control) Minimum=1 Maximum=5 High=better outcome

Description: Will compare mean change scores across the two conditions (mindset and control)

Description: Will compare mean change scores across the two conditions (mindset and control)

Description: Will compare mean change scores across the two conditions (mindset and control)

Description: Will compare mean change scores across the two conditions (mindset and control)

Description: Will compare mean scores during relevant trials of the Social Evaluation Task across the two conditions (mindset and control)

Other Outcomes

Description: Will compare mean levels of cingulo-opercular network activation during resting state and relevant trials of the Social Evaluation Task and Go/no go Task across the two conditions (mindset and control)

Description: Will compare mean levels of cingulo-opercular network-amygdala connectivity during resting state and relevant trials of the Social Evaluation Task and Go/no go Task across the two conditions (mindset and control)

Description: Will conduct exploratory whole-brain analyses comparing activation patterns during resting state and relevant trials of the Social Evaluation Task and Go/no go Task across the two conditions (mindset and control)

Description: Will compare mean change scores across the two conditions (mindset and control)

Description: Will compare mean change scores across the two conditions (mindset and control)

Description: Will compare mean change scores across the two conditions (mindset and control)

Description: Will compare mean change scores across the two conditions (mindset and control)

Primary Outcomes

Description: # of participants screened per month

Description: # of participants enrolled per month

Description: % participants that complete all study visits

Secondary Outcomes

Description: Proportion of participants who withdraw or terminated by investigators and reasons why

Description: Proportion of participants with AE/UP

Description: Slope of the most linear portion of the vertical ground reaction force curve, during early stance.

Description: Maximum slope of the most vertical portion of the vertical ground reaction force curve between successive data points, during early stance.

Description: WOMAC questionnaire, pain sub scale 0-20

Description: Visual analog scale, 0-100

Description: Assessed using hand held algometer

Primary Outcomes

Description: by mean change in PaO2/FiO2 (PaO2=Partial pressure of oxygen; FiO2= Fraction of inspired oxygen)

Secondary Outcomes

Description: demonstrated by bacterial or fungal culture

Description: defined by HS (Hemophagocytic Syndrome) score

Primary Outcomes

Description: Inpatients are considered as clinically improved if they have gained at least 2 points on the following clinical evaluation scale, or if they went back home Clinical evaluation scale :1. Outpatient back to normal activities / 2. Outpatient without normal activities / 3. Inpatient without oxygen therapy / 4. Inpatient with oxygen therapy/ 5. Inpatient requiring either nasal high-flow oxygen therapy or non-invasive respirator or both / 6. Inpatient, requiring either ExtraCorporeal Membrane Oxygenation (ECMO) or invasive artificial respirator, or both / 7. Deceased.

Primary Outcomes

Description: The incidence of SARS CoV-2 infection will be confirmed by PCR or antigen test

Secondary Outcomes

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will required hospital admission because of Covid-19

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will required ICU admission because of Covid-19

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will develop pneumonia because of Covid-19

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will require oxygen support because of Covid-19

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will develop gastrointestinal symptoms because of Covid-19

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with body's temperature > 37.5 ºC during the course of the disease

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with cough during the course of the disease

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with fatigue during the course of the disease

Description: Use of drugs (dosis and duration of the treatment) for Covid-19 treatment

Primary Outcomes

Description: Number of deceased participants or with persistant organ dysfunction (dependency on mechanical ventilation, new renal replacement therapy, or vasopressors).

Secondary Outcomes

Description: Number of whole and part study days for which the patient is alive and not admitted to an intensive care unit

Description: Number of study days in ICU without persistant organ dysfunction

Description: Mortality at 6 months

Description: Assessed by the EQ-5D-5L EuroQol questionnaire (EQ-5D-5L). The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ-5D visual analog scale (EQ VAS). The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The patient is asked to indicate her/his health state by ticking the box next to the most appropriate statement in each of the 5 dimension. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the 5 dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ-VAS records the patient's self-rated health on a vertical visual analog scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'.

Description: Assessed by the Sequential Organ Failure Assessment (SOFA) score. Used to track a person's status during the stay in an intensive care unit to determine the extent of a person's organ function or rate of failure. The score is based on six different sub-scores, one each for the respiratory (PaO2/fraction of inspired oxygen FiO2) mmHg), cardiovascular (mean arterial pressure OR administration of vasopressors required), hepatic (liver bilirubin mg/dl [µmol/L]), coagulation (platelets x 103/µl), renal (kidneys creatinine (mg/dl) [µmol/L] (or urine output)), and neurological (Glasgow coma scale). The sub-score of each system ranges from 0 (best) to +4 (worst).

Description: Assessed by serum lactate concentration

Description: Assessed by interleukin-1 beta (IL-1ß), tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP).

Description: Assessed by procalcitonin (PCT).

Description: Assessed by thrombomodulin (TM) and angiopoietin-2 (ANG-2).

Description: Assessed by Kidney Disease: Improving Global Outcomes (KDIGO) criteria

Description: clinician judgment of hemolysis, as recorded in the chart, OR hemoglobin drop of at least 25 g/L within 24 hours of a dose of investigational product plus 2 of the following: reticulocyte count >2 times upper limit of normal at clinical site lab; haptoglobin 2 times upper limit of normal at clinical site lab; lactate dehydrogenase (LDH) >2 times upper limit of normal at clinical site lab. Severe hemolysis: o hemoglobin <75 g/L AND at least 2 of the above criteria AND requires 2 units of packed red blood cells.

Description: Core lab-validated glucose level <3.8 mmol/L

Primary Outcomes

Description: Fraction of oxygen-saturated hemoglobin relative to the patient's total blood hemoglobin, represented as a percentage. Measurement using the pulse oximeter of the multi-parameter vital signs monitor. Measurement units % SpO2.

Description: Balance between the production of heat by the body and its loss. Measurement using an infrared thermometer. Units of measure degrees centigrade.

Description: Force exerted by the blood against the walls of the vessels (arteries) as it is pumped by the heart. Measurement using the multi-parameter vital signs monitor. Units of measurement in mmHg. Obtain systolic and diastolic pressure.

Description: Number of times the heart beats for a certain period of time, measured by the multi-parameter vital signs monitor. Units of measure beats per minute.

Description: Number of breaths that a living being takes during a certain period of time, Count daily with the patient at rest the number of breaths for one minute each time the chest rises. Measured in breaths per minute.

Description: Disruption of the organic functions of any living being. The existence of the death certificate will be reviewed daily. Categories: dead or alive.

Description: Simultaneous knowledge, in the unity of time, of oneself (subject) and of the surrounding world (object), is the reflection of reality. It will be evaluated daily with the glasgow scale. Categories: 1.13-15 points. 2. 9-12 points. 3. 3-8 points.

Description: Number of days that the patient remains hospitalized. It is reviewed daily if the patient has been discharged. Categories: 1.Hopitalized. 2. Released.

Description: Rapid sequential evaluation of organic failures. Evaluate daily the qSOFA items and get your score. Measure in points.

Description: Clinically and study-based acquired need to open the airway in order to supply him with oxygen. Check daily if a cannula or tube was placed in the windpipe. Categories: 1.Progress to ventilation. 2. Does not progress to ventilation.

Description: Need for a multidisciplinary team, for presenting an acute critical state, with the support of technological resources for monitoring, diagnosis and treatment. It is reviewed daily if the patient is directed to ICU. Categories: 1.Enter ICU. 2. You do not enter ICU.

Description: Any localized painful discomfort in the head. Evaluate and ask for pain by numbering it from 1-10, where 0 is the absence and 10 is the greatest intensity (Daily, 2 shifts, 21 days).

Description: Physical actions that you can take without pain or discomfort. Evaluate what movements and activities he tolerates (Daily, 2 shifts, 21 days). Categories: 1.Walk. 2.He can stand 3.Sit. 4.Postrate.

Description: Body postures that are used to facilitate the examination of the patient, his treatment, the prevention of injuries due to immobility, and his comfort when he is bedridden. Observe the anatomical position in which he is found (Daily, 2 shifts, 21 days). Categories: 1. In the prone position. 2.In the supine position. 3.Fowler. 4.Semifowler. 5.Other

Description: Evaluate the level of hydration of the hair (Daily, morning, 21 days). Categories: 1.Hydrated, shiny. 2.Opaque. 3.Very dull and dry.

Description: Evaluate hair loss with the "pull sign" by pulling the hair without the intention of plucking, daily in the morning (Daily, morning, 21 days).Categories 1. <5 hairs on hand. 2. 5-10 hairs. 3.> 10 hairs.

Description: Targeted search for one or more asymptomatic sudden onset decalvary patches throughout the hair territory (Daily, morning, 21 days). Categories: 1. Without decalvary plates. 2. With regional decalvary plates. 3. Generalized alopecia areata.

Description: Inspect the scalp for lesions (Daily, morning, 21 days). Categories: 1.No injuries. 2. Flaking. 3.Erythema. 4.Infection. 5. Bleeding.

Description: Ask about itching of the scalp (Daily, morning, 21 days). Categories: 1.Without itching. 2.Itching.

Description: Evaluate the absence or loss of eyelashes, daily in the morning. Categories: 1.Without alterations. 2.White spaces. 3. Fall when exploring.

Description: Evaluate the absence or drooping of eyebrows (Daily, morning, 21 days). Categories: 1. Without alterations. 2.White spaces. 3. Fall when exploring.

Description: Evaluate eyelid edema (Daily, morning, 21 days). Categories: 1. Without edema. 2. With edema

Description: Check the vascularity of the sclera (Daily, morning, 21 days). Categories: 1.White sclera. 2.Small blood vessels. 3. Large blood vessels. 4.Hemorrhage.

Description: Assess ocular hydration (Daily, morning, 21 days). Categories: 1.Hydrated. 2.Dry mucus. 3.Absence of tears. 4 sunken eyes

Description: Evaluate sclera color, daily in the morning. Categories: 1.White. 2. Localized yellow. 3.General yellow. 4.Other colors.

Description: Evaluation of smell, presenting non-irritating odors and ask if it distinguishes them (Daily, morning, 21 days). Categories: 1.Normal. 2. Hyposmia. 3.Anosmia.

Description: Evaluate the presence of irritation in the nostrils (Daily, morning, 21 days). Categories: 1.No irritation. 2.With irritation.

Description: Assess nasal secretions (Daily, morning, 21 days). Categories: 1. Absence. 2.Transparent. 3.Of other colors. 4.With blood.

Description: Evaluate the presence of cheilitis (Daily, morning, 21 days). Categories: 1.Without cheilitis. 2.Unilateral. 3.Bilateral. 4.With ulcers.

Description: Assess taste buds (Daily, morning, 21 days). Categories: 1. Normal. 2. Inflamed. 3. Painful. 4. Bleeding.

Description: Evaluate the presence of the saw edge of the tongue (Daily, morning, 21 days). Categories 1.Normal. 2.Flat 3.With serrated edge.

Description: Look for changes in the body of the tongue (Daily, morning, 21 days). Categories: 1.No alterations. 2.Geographic. 3.Fissured.

Description: Look for changes in the thickness of the tongue (Daily, morning, 21 days). Categories: 1. Normal thickness. 2. Abnormal thickness, swollen.

Description: Assess the presence of salivation (Daily, morning, 21 days). Categories: 1.Normal. 2.Excessive salivation. 3 absent.

Description: Evaluate the taste presenting food from their tray and ask if you distinguish the flavors (Daily, morning, 21 days). Categories: 1.Conserved. 2. Hypogeusia. 3.Ageusia.

Description: Evaluation of the gums (Daily, morning, 21 days). Categories: 1.Normal. 2.Hypersensitive 3.Inflamed. 4. Bleeding.

Description: Evaluation of skin sensitivity (Daily, morning, 21 days). Categories: 1.Normal. 3.Altered sensitivity. 3.Painful.

Description: Assess the presence of lesions (Daily, morning, 21 days). Categories: 1. No lesions. 2.Dermatitis. 3. Open lesions.

Description: Assess skin hydration (Daily, morning, 21 days). Categories: 1.Normal. 2.Fat. 3.Dry.

Description: Evaluate skin texture (Daily, morning, 21 days). Categories: 1.Lisa. 2.Rugose. 3.Descamative

Description: Check for loss or absence of body hair (Daily, morning, 21 days). Categories: 1.Present. 2.Fall. 3.Absence.

Description: Evaluate by finger pressure the 7th cervical hypersensitivity (Every 2 days, morning, 21 days). Categories: 1. It does not cause pain. 2. It causes pain.

Description: Search for hypersensitivity on the inside of the forearm (Every 2 days, morning, 21 days)

Description: Ask if he presents odynophagia (Daily, 2 shifts, 21 days). Categories: 1.Absent. 2. Present.

Description: Evaluation of the presence of cough (Daily, 2 shifts, 21 days). Categories: 1.Absent. 2.Productive. 3.Dry

Description: Evaluation of the presence of sneezing (Daily, 2 shifts, 21 days). Categories: 1. Absent. 2. Present.

Description: Respiration rhythm evaluation (Daily, 2 shifts, 21 days). Categories: 1. Normal. 2.Altered.

Description: Assessment of abdominal breathing (Daily, 2 shifts, 21 days). Categories: 1.Absent. 2. Present.

Description: Evaluation of the use of accessory muscles when breathing (Daily, 2 shifts, 21 days). Categories: 1.Absent. 2. Present.

Description: Evaluate the presence of xiphoid retraction when breathing (Daily, 2 shifts, 21 days). Categories: 1. Absent. 2. Present.

Description: Assess the presence and degree of dyspnea (Daily, 2 shifts, 21 days). Categories: 1.Without difficulty. 2.When standing. 3.When sitting. 2.When speaking, 3.Lying down.

Description: Evaluate the abdomino-cutaneous reflexes (Diary, verpertino, 21 days). Categories: 1. Present. 2. Absent

Description: Assess rebound sensitivity (Daily, verpertino, 21 days). Categories: 1. Without sensitivity. 2. With sensitivity.

Description: Evaluate the presence of pain in the right hypochondrium. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Description: Evaluate the presence of pain in the epigastrium. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Description: Evaluate the presence of pain in the left hypochondrium. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Description: Assess the presence of pain in the right flank. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Description: Assess the presence of pain in the mesogastrium (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Description: Evaluate the presence of pain in the left flank. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Description: Evaluate the presence of pain in the right iliac fossa. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Description: Evaluate the presence of pain in the hypogastrium. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Description: Assess the presence of pain in the left iliac fossa. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Description: Ask for the presence of vomiting in 24 hours (Daily, evening, 21 days). Categories: 1. Absent. 2. Present.

Description: Ask about the presence of appetite (Daily, evening, 21 days). Categories: 1. Increased appetite. 2.Normal 3.Hypoexia. 4.Anorexia.

Description: Ask about the presence of reflux (Daily, evening 21 days). Categories: 1. Absent. 2. After eating (specify food). 3. At bedtime. 4. Sudden

Description: Ask about the presence of more common burps than normal (Daily, evening, 21 days). Categories: 1.Normales 2. Augmented.

Description: Evaluation of defecation by means of bowel movements with the Bristol scale (Daily, evening, 21 days). Categories: 1.Normal (T3, T4) 2.Constipation (T1, T2). 3. Diarrhea (T5, T6, T7).

Description: Evaluation of hair loss on legs (Every 2 days, evening, 21 days) Categories: 1. Without alterations. 2.White spaces. 3. Fall when exploring.

Description: Evaluation of the sensitivity of the tibial tract (Every 2 days, evening, 21 days) Categories: 1. No pain. 2.Painful.

Description: Assessment of nail strength (Every 2 days, evening, 21 days). Categories: 1. Strong. 2. Brittle. 3.Not assessable.

Description: Check the presence of fungus in the nails of the hands (Every 2 days, evening, 21 days). Categories: 1. Absent. 2. Present. 3.Not assessable.

Description: Look for the presence of white stripes on the nails (Every 2 days, evening, 21 days). Categories: 1. Absent. 2. Present. 3.Not assessable.

Description: Look for the presence of white spots on the nails (Every 2 days, evening, 21 days). Categories: 1. Absent. 2. Present. 3.Not assessable.

Description: Look for the presence of ridges on the nails (Every 2 days, evening, 21 days). Categories: 1.Lisas. 2.With ridges. 3.Not assessable.

Description: Taking the height (at the beginning of the protocol). Measure in cm.

Description: Weight taking (Every 2 days, 2 hours after breakfast, for 21 days). Measured in kg.

Description: Calculation of BMI (Every 2 days, morning, for 21 days). Measured in kg / m2.

Description: Measurement by blood sample of erythrocytes (Every 3 days, for 21 days). Measured at 10 ^ 6 / uL.

Description: Measurement by blood sample of hemoglobin (Every 3 days, for 21 days). Measured in g / dL.

Description: Measurement by blood sample of hematocrit (Every 3 days, for 21 days). Measurement in %.

Description: Measurement by blood sample of mean corpuscular volume (MCV) (Every 3 days, for 21 days). Measured in fL.

Description: Measurement by blood sample of mean hemoglobin concentration (Every 3 days, for 21 days). Measurement in pg.

Description: Measurement every 3 days by blood sample of mean corpuscular hemoglobin concentration (Every 3 days, for 21 days). Measured in g / dL

Description: Erythrocyte distribution width measurement by blood sample (Every 3 days, for 21 days). Measured in%.

Description: Measurement by blood sample of the hemoglobin distribution index (Every 3 days, for 21 days). Measured in g / dL.

Description: Measurement by blood sample of leukocytes (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

Description: Measurement by blood sample of neutrophils (%) (Every 3 days, for 21 days). Measurement in%

Description: Measurement by blood sample of neutrophils (#) (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

Description: Measurement by blood sample of lymphocytes (%) (Every 3 days, for 21 days). Measurement in%

Description: Measurement by blood sample of lymphocytes (#) (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

Description: Measurement by blood sample of monocytes (%) (Every 3 days, for 21 days). Measurement in%

Description: Measurement by blood sample of monocytes (#) (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

Description: Measurement by blood sample of eosinophils (%) (Every 3 days, for 21 days). Measurement in%

Description: Measurement by blood sample of eosinophils (#) (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

Description: Measurement by blood sample of basophils (%) (Every 3 days, for 21 days). Measurement in%

Description: Measurement by blood sample of basophils (#) (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

Description: Measurement of prothrombin time (PT) by blood sample (Every 3 days, for 21 days). Measure in seconds

Description: Measurement by blood sample of INR (Every 3 days, for 21 days). Measure in units

Description: Measurement by control blood sample (100-50) (Every 3 days, for 21 days). Measure in seconds

Description: Measurement by blood sample of partial thromboplastin time (Every 3 days, for 21 days). Measure in seconds

Description: Measurement by control blood sample (100-50) (Every 3 days, for 21 days). Measure in seconds

Description: Measurement by blood sample of platelets. Measured in 10 ^ 3 / μL

Description: Measurement by blood sample of mean platelet volume (MPV) (Every 3 days, for 21 days). Measured in fL.

Description: Initial screening test to diagnose patients with signs or symptoms suggestive of venous thromboembolism, it is a marker of endogenous fibrinolysis. Measurement by blood sample of dimer D (Every 3 days, for 21 days). Measured in ng / mL

Description: Sulfur amino acid that originates in the metabolism of methionine, and is very aggressive for the arterial endothelium. Measurement by blood sample of homocysteine levels (Every 3 days, for 21 days). Measured in µmol / l.

Description: Fat-soluble vitamin involved in calcium homeostasis and bone metabolism, regulation of genes involved in the regulation of cell proliferation, cell differentiation and apoptosis. It has been suggested that it exerts immunomodulatory and antiproliferative effects. Measurement by blood sample of levels of 25-hydroxycholecalciferol (Every 3 days, for 21 days). Measured in nmol / L

Description: Measurement by blood sample of calcium (Every 3 days, for 21 days). Measured in mg / dL.

Description: Measurement by blood sample of phosphorus (Every 3 days, for 21 days). Measured in mg / dL.

Description: Measurement by blood sample of magnesium (Every 3 days, for 21 days). Measured in mg / dL.

Description: Measurement by blood sample of sodium (Every 3 days, for 21 days). Measured in mmol / L.

Description: Measurement by blood sample of potassium (Every 3 days, for 21 days). Measured in mmol / L.

Description: Measurement by blood sample of chlorine (Every 3 days, for 21 days). Measured in mmol / L.

Description: A measure of the concentration of free glucose in the blood, serum or blood plasma. Measured in mg / dL.

Description: Taking a blood sample of total cholesterol (Every 3 days, for 21 days). Measured in mg / dL.

Description: Taking a blood sample of triglycerides (Every 3 days, for 21 days). Measured in mg / dL.

Description: Taking a blood sample of LDL cholesterol (Every 3 days, for 21 days). Measured in mg / dL.

Description: Taking a blood sample for HDL cholesterol (Every 3 days, for 21 days). Measured in mg / dL.

Description: Taking a blood sample to evaluate the level of aspartate aminotransferase (Every 3 days, for 21 days). Measured in U / L.

Description: Taking a blood sample to evaluate the level of alanine aminotransferase (Every 3 days, for 21 days). Measured in U / L.

Description: Taking a blood sample to evaluate the total bilirubin level (Every 3 days, for 21 days). Measured in mg / dL.

Description: Taking a blood sample to evaluate the level of direct bilirubin (Every 3 days, for 21 days). Measured in mg / dL.

Description: Taking a blood sample to evaluate the level of indirect bilirubin (Every 3 days, for 21 days). Measured in mg / dL.

Description: Taking a blood sample to evaluate the level of alkaline phosphatase (Every 3 days, for 21 days). Measured in U / L.

Description: Taking a blood sample to evaluate the level of total proteins (Every 3 days, for 21 days). Measured in g / dL.

Description: Taking a blood sample to evaluate the albumin level (Every 3 days, for 21 days). Measured in g / dL.

Description: Taking a blood sample to evaluate the globulin level (Every 3 days, for 21 days). Measured in g / dL.

Description: Taking a blood sample to evaluate the A / G ratio (Every 3 days, for 21 days). Measured in g / dL.

Description: ake a blood sample to evaluate the levels of urea nitrogen (Every 3 days, for 21 days). Measured in mg / dL.

Description: Take a blood sample to evaluate urea levels (Every 3 days, for 21 days). Measured in mg / dL.

Description: Take a blood sample to evaluate creatitine levels (Every 3 days, for 21 days). Measured in mg / dL.

Description: Take a blood sample to evaluate uric acid levels (Every 3 days, for 21 days). Measured in mg / dL.

Description: Take a blood sample to evaluate ferritin levels (Every 3 days, for 21 days). Measured in ng/mL.

Description: Take a blood sample to evaluate fibrinogen levels (Every 3 days, for 21 days). Measured in mg / dL.

Description: Take a blood sample to evaluate the levels of C-reactive protein (Every 3 days, for 21 days). Measured in mg/L.

Description: Use of the appropriate procedures established in the NSS indications (Specific supplementation scheme, based on 1 sachet, intramuscular B vitamins and probiotics). Quantification of empty supplement envelopes (Daily, 2 shifts, 21 days). Categories: 1.On empty. 2. About half. 3.Full.

Description: Quantification of the time from when the envelope is added in water, until everything is consumed (Daily, 2 shifts, 21 days). Categories: 1. Less than 15 minutes. 2. More than 15 minutes.

Description: Quantification of the amount of prepared "NSS" he drink (Daily, 2 shifts, 21 days). Categories: 1.All the preparation. 2.Half. 3.Nothing.

Description: In-person verification of the taking of the floratil pill and observe that they do not vomit it (Daily, 2 shifts, first 6 days). Categories: 1. The pill is taken. 2.The pill is not taken.

Description: Corroborate in person the correct application of the neurobion injection (Daily, evening, first 5 days). Categories: 1. It applies. 2.Not applicable.

Description: Unit of thermal energy, which is equal to the amount of heat needed to raise the temperature of 1 gram of water by 1 degree Celsius. Unit of measurement of the energy content of food that consists of the number of calories that a given weight of food can develop in the tissues, or in the physical work equivalent to them. Calculate the grams that the food has of each macronutrient and multiply it by the energy intake. Based on the Mexican Equivalent Food System. Number in Kcal.

Description: Evaluate the amount of trans fat in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

Description: Evaluate the amount of saturated fat in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

Description: Evaluate the amount of monounsaturated fats in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

Description: Evaluate the amount of polyunsaturated fat in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

Description: Evaluate the amount of protein of animal origin in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

Description: Evaluate the amount of plant-based protein in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

Description: Accurate record of the amount of fluids administered. Evaluate the income of 24 hrs. (Daily, 2 shifts, 21 days). Number in ml.

Description: Accurate record of the amount of liquids eliminated by any means. Evaluate the expenses of 24 hrs. (Daily, 2 shifts, 21 days). Number in ml.

Description: Need or desire to eat. Observe the percentage of the tray with food that was ingested (Daily, 2 shifts, 21 days). Categories: 1. 100% ingested. 2.75%. 3.50%. 4.25%.

Description: Cardiovascular disease risk indicator. Measure with a tape measure with the patient standing, feet together, arms at the sides and the abdomen relaxed, encircling the abdomen at the level of the navel at the midpoint between the last rib and the iliac crest and without pressing, taking an inspiration deep, taking the measurement at the moment of expelling the air.

Description: It is used to know the nutritional status of the patient. It is obtained by measuring the middle part of the arm with a tape measure, taking as a reference the length between the point of the shoulder (acromion) and the head of the radius (olecranon). Take the circumference of the arm using a tape measure (every 2 days, 2 hours after breakfast, in the morning, for 21 days). Measure in mm.

Description: It is measured on the midline of the back of the arm (triceps) at 1 cm from the height of the midpoint of the arm. Taking triceps fold measuring tape and caliper (every 2 days, 2 hours after breakfast, morning, for 21 days)). Measure in mm.

Description: Calculation from arm circumference and triceps fold. Calculate it according to the formula proposed by Frisancho. (every 2 days, 2 hours after breakfast, morning, for 21 days). Measure in mm2.

Description: Set of peculiarities that characterize the individuals of a species, dividing them into male and female, and make possible a reproduction characterized by genetic diversification. Based on an official ID. Categories: 1. Male 2. Female

Description: Time elapsed from the birth of a living being to the moment the calculation is made. Based on an official ID. Number between 30 and 75.

Description: Sugars attached to the surface of red blood cells, and according to their composition. Evaluate by blood sample. Categories: 1.A, 2. B, 3.AB 4.O.

Description: Protein in red blood cells or erythrocytes. Obtaining by blood sample. Categories: 1.Rh (+) 2.Rh (-).

Secondary Outcomes

Description: Record the use of proton pump inhibitors (omeprazole, pantoprazole) (daily, evening, for 21 days). Categories: 1.Not prescribed. 2.Prescribed.

Description: Record the use of obesity medications (orlistat, acarbose, bile acid sequestrants, etc.) (daily, evening, for 21 days). Categories: 1.Not prescribed. 2.Prescribed.

Description: Record the use of antiepileptic drugs (daily, evening, for 21 days). Categories: 1.Not prescribed. 2.Prescribed.

Description: Record the use of oral contraceptives (daily, evening, for 21 days). Categories: 1.Not prescribed. 2.Prescribed.

Description: Record the use of antimitotics (colchicine) (daily, evening, for 21 days). Categories: 1.Not prescribed. 2.Prescribed.

Description: Chemical substance that kills or prevents the growth of certain classes of sensitive microorganisms. Record the antibiotics that are being administered. (daily, evening, for 21 days) Categories: 1.Not used. 2.Use of antibiotics (specify which)

Description: Medicines whose main pharmacological effect is to relieve pain. Record the analgesics that are being administered (daily, evening, for 21 days). Categories: 1.Not used. 2.Use of analgesics (specify which)

Description: Drugs with anti-inflammatory and immunosuppressive effect. Record the corticosteroids that are being administered (daily, evening, for 21 days). Categories: 1.Not used. 2.Use of corticosteroids (specify which).

Description: Substance that causes the elimination of water and electrolytes from the body through urine. Record the diuretics that are being administered (daily, evening, for 21 days). Categories: 1.Not used. 2.Use of diuretics (specify which)

Description: Drugs used to lower blood pressure. Record the antihypertensive drugs that are being administered (daily, evening, for 21 days). Categories: 1.Not used. 2.Use of antihypertensives (specify which)

Description: Endogenous or exogenous substance that interferes with or inhibits blood clotting, creating an antithrombotic or prohemorrhagic state. Record the anticoagulants that are being administered (daily, evening, for 21 days). Categories: 1.Not used. 2.Use of anticoagulants (specify which)

Description: Medications that attend to a basic pathology and have not been considered in the previous variables. Record the medications that are being administered and have not been named before (daily, evening, for 21 days). Write the medications.

Description: Disturbance of the normal state of the level of absorption acutely due to a pathological alteration. Record the acute alterations that affect the absorption of nutrients (daily, evening, for 21 days). Categories: 1.None. 2.Intolerance. 3. Allergies 4. Diarrhea 5. Infection or inflammation in any organ of the digestive system.

Description: Any alteration in the response to the action of the drug due to the concomitant reaction of another chemical substance. Side effects reported through the clinic and laboratory (daily, evening, for 21 days). Categories: 1.None. 2.Rash. 3.Head or dizziness. 4.Gastrointestinal pain. 5.Other (specify).

Description: Artificial supply of oxygen (O2) in the inspired air; its main objective is tissue oxygenation. Check the quantity of liters that you have pre-written for 24 hours (daily, evening, for 21 days). Number of liters.

Description: Attitude or disposition in emotional life. It is not a transitory emotional situation. It is a state, a way of staying, of being, whose duration is prolonged and fades over the rest of the psychic world. Assess the patient's state of mind (daily, evening, for 21 days). Categories: 1.Happy. 2.Relaxed. 3. Alert. 4. Annoying 5. Sad. 6.Tense. 7.Tired. 8.Depressed

Primary Outcomes

Description: This is being measured with the Subject Unit of Distress Scale.

Description: This is being measured with the GAD-7 questionnaire.

Description: This is being measured with the Psychological Insecurity Scale.

Secondary Outcomes

Description: This is being measured with the WHO-5 Well-being Index questionnaire.

Description: This is being measured with the Fear of COVID-19 Scale.

Primary Outcomes

Description: PaO2/FiO2 ratio

Secondary Outcomes

Description: PaO2/FiO2 ratio : a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19. Blood pressure in mmHg will be measured

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19. Cardiac frequency in beats per minute will be assessed

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19. Sinus rythm will be assessed

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19. Vasopressors and inotropes drugs use will be reported

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19. EKG : PR, QRS, QTc intervals in ms will be measured

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.

Primary Outcomes

Description: Pulmonary lesion area will be taken by a chest x-ray or computed axial tomography

Description: Aretrial oxygen saturation will be taken by an oximeter

Description: Number of days of patient discharge

Secondary Outcomes

Description: Blood samples will be taken on days 1, 3, 7, 15, 20, 25

Description: Blood samples will be taken on days 1, 3, 7, 15, 20, 25

Description: Blood samples will be taken on days 1, 3, 7, 15, 20, 25

Description: Blood samples will be taken on days 1, 3, 7, 15, 20, 25

Primary Outcomes

Description: The change in physician end-of-shift heart rate variability will be measured using the Hexoskin Smart Shirt. The Hexoskin shirt contains three sensors to capture participant heart rate via ECG, respiratory rate, minute ventilation, and movement/activity. Changes in HRV will be averaged over the two post-intervention shift data collections to control for an anticipated shift-to-shift and patient-to-patient variability in stress response due to patient acuity and workload

Description: The change in physician end-of-shift anxiety measured by the State-Trait Anxiety Inventory (STAI) for physicians exposed to the simulation based training preparation compared to standard guideline update delivery. Each STAI item is given a weighted score of 1 to 4. A rating of 4 indicates the presence of a high level of anxiety for items (e.g., "I feel frightened," "I feel upset"). To obtain scores for the S-Anxiety, simply add the weighted scores for the twenty items that make up the scale, taking into account the fact that the scores are reversed for specific items. Scores for the S-Anxiety scale can vary from a minimum of 20 to a maximum of 80.

Description: The secondary outcome of interest is change in anxiety between the intervention and control conditions as measured by the State-Trait Anxiety Inventory (STAI). The T-Anxiety scale (STAI Form Y-2) consists of twenty statements that assess how people generally feel. The scoring weights for the anxiety-present items are the same as the chosen numbers on the print inventory form. To obtain scores for the T-Anxiety scale, simply add the weighted scores for the twenty items that make up the scale, taking into account the fact that the scores are reversed for specific items. Scores for the T- Anxiety scales can vary from a minimum of 20 to a maximum of 80.